somatostatin
AssetAlso called COLIRIOBCN070660, SRIF-14
Activates somatostatin receptors to protect retinal neurons and reduce retinal vascular dysfunction.
- Stage
- Phase 2, no development reported
- Modality
- Peptide
- Target
- SSTR2
- 1
- Indication
- 17
- Trials
- 1
- Developer
No development reported since November 2015. Last activity: Trial NCT01726075 completed. clinicaltrials.gov
Indications
1Diabetic retinopathy
Phase 2, Completed, NCT01726075, clinicaltrials.gov, Nov 1, 2026
In the full profile
- Target and mechanism5
- Owner and partners1
- Trials17
- Evidence for its targets4
- Competitors12
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.